AtriCure vs Glaukos
AtriCure reported revenue of $534 million in fiscal 2025, about the same as Glaukos' $507 million in fiscal 2025. AtriCure's revenue grew 14.9% in its latest year, and Glaukos' grew 32.3%. AtriCure had an operating margin of -1.8%, against -39.3% at Glaukos. Free cash flow was $48 million at AtriCure and −$22 million at Glaukos.
Side by side
| AtriCure | Glaukos | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $534M | $507M |
| Revenue growth | 14.9% | 32.3% |
| Revenue growth a year, last 5 years | 20.9% | 17.7% |
| Gross margin | 75.0% | 55.7% |
| Operating margin | −1.8% | −39.3% |
| Net margin | −2.1% | −37.0% |
| Free cash flow | $48M | −$22M |
| Free cash flow margin | 9.0% | −4.4% |
| Return on capital | −1.9% | — |
| Net debt to EBITDA | −8.9x | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 1.7% | 8.4% |
| Last close | $56.84 | $245.72 |
| P/E at the last close | 189.5× | — |
| Insider trades, last 12 months | sold $4.4 million | sold $80.3 million |
| Piotroski F-score | 7 of 9 | — |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
AtriCureGlaukos
Operating margin
Percent of revenue
AtriCureGlaukos
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
AtriCureGlaukos